SKYE beat EPS expectations by 5.66%
Nov 16, 2025, 11:33 AM
0.00%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Skye Bioscience (SKYE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Skye Bioscience's actual EPS was -$0.32, beating the estimate of -$0.34 per share, resulting in a 5.66% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.